KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Liabilities and Shareholders Equity: 2011-2025

Historic Liabilities and Shareholders Equity for Travere Therapeutics (TVTX) over the last 14 years, with Sep 2025 value amounting to $538.6 million.

  • Travere Therapeutics' Liabilities and Shareholders Equity rose 6.77% to $538.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 billion, marking a year-over-year decrease of 10.81%. This contributed to the annual value of $594.1 million for FY2024, which is 24.69% down from last year.
  • Latest data reveals that Travere Therapeutics reported Liabilities and Shareholders Equity of $538.6 million as of Q3 2025, which was down 3.01% from $555.3 million recorded in Q2 2025.
  • In the past 5 years, Travere Therapeutics' Liabilities and Shareholders Equity ranged from a high of $832.9 million in Q3 2023 and a low of $504.4 million during Q3 2024.
  • Over the past 3 years, Travere Therapeutics' median Liabilities and Shareholders Equity value was $594.1 million (recorded in 2024), while the average stood at $647.5 million.
  • Per our database at Business Quant, Travere Therapeutics' Liabilities and Shareholders Equity surged by 33.33% in 2021 and then plummeted by 39.44% in 2024.
  • Travere Therapeutics' Liabilities and Shareholders Equity (Quarterly) stood at $776.6 million in 2021, then declined by 13.40% to $672.6 million in 2022, then climbed by 17.30% to $788.9 million in 2023, then fell by 24.69% to $594.1 million in 2024, then grew by 6.77% to $538.6 million in 2025.
  • Its last three reported values are $538.6 million in Q3 2025, $555.3 million for Q2 2025, and $548.8 million during Q1 2025.